Incidence and onset of delayed seizures after overdoses of extended-release bupropion

American Journal of Emergency Medicine

Volumn 27, Issue 8, 2009, Pages 911-915

  Starr, Paul ^a   Klein Schwartz, Wendy ^a   Spiller, Henry ^b   Kern, Perri ^c   Ekleberry, Susan E ^d   Kunkel, Susan ^e  

^a UNIVERSITY OF MARYLAND   (United States)

^b KENTUCKY REGIONAL POISON CENTER   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; CHILD; CONTROLLED STUDY; DRUG OVERDOSE; FEMALE; HALLUCINATION; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; INGESTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SYMPTOMATOLOGY; TREMOR;

ADOLESCENT; ADULT; AGED; BUPROPION; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; OBSERVATION; OVERDOSE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEIZURES; STATISTICS, NONPARAMETRIC;

EID: 70349185366     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2008.07.004     Document Type: Article

References (13)

1. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 50 7 (1989) 256-261
2. Product Information: WELLBUTRIN XL(R) extended release oral tablets, bupropion hcl extended release oral tablets (2006), GlaxoSmithKline, Research Triangle Park, NC
3. Hesse L.M., He P., Krishnaswamy S., Hao Q., Hogan K., von Moltke L.L., Greenblatt D.J., and Court M.H. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14 4 (2004) 225-238
4. Stahl S., Pradko J., Haight B., Modell J., Rockett C., and Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 6 4 (2004) 159-166
5. Spiller H.A., Ramoska E.A., and Krenzelok E.P. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emer Med 12 (1994) 43-45
6. Shepherd G., Velez L.I., and Keyes D.C. Intentional bupropion overdoses. J Emerg Med 27 2 (2004) 147-151
7. POISINDEX System [database on CD-ROM]. Version 5.1. Greenwood Village, Colo: Thomson Healthcare.
8. Colbridge M.G., Dargan P.I., and Jones A.L. Bupropion-the experience of the National Poisons Information Service (London). J Toxicol Clin Toxicol 40 3 (2002) 398-399
9. Belson M.G., and Kelley T.R. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med 23 3 (2002) 223-230
10. Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy 25 10 (2005) 1378-1382
11. Benson, Spyker D.A., Troutman W.G., and Watson W.A. TESS-based dose-response using pediatric clonidine exposures. Toxicol Appl Pharmacol 213 (2006) 145-151
12. Bronstein A.C., Spyker D.A., Cantilena Jr. L.R., Green J., Rumack B.H., and Heard S.E. 2006 Annual report of the American Association of Poison Control Centers National Poison Data System (NPDS). Clin Toxicol 45 8 (2007) 815-917
13. Hoffman R. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol (Phila) 45 8 (2007) 943-945 Editorial